Search
Betamethasone phosphate
go.drugbank.com/drugs/DB14669ApprovedVet approved[L11994] Betamethasone sodium phosphate was granted FDA approval on 3 March 1965.[L11994] … Betamethasone phosphate is a prodrug that is rapidly hydrolyzed, providing rapidly accessible [betamethasone] to agonize glucocorticoid receptors.
Maftivimab
go.drugbank.com/drugs/DB15899ApprovedInvestigational[A221825] Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and high … Ebola virus (EBOV) remains an important human pathogen within the _Ebolavirus_ genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%.
Deferiprone
go.drugbank.com/drugs/DB08826ApprovedInvestigationalThalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. … FDA approved on October 14, 2011.
Categories: Compounds used in a research, industrial, or household settingVelpatasvir
go.drugbank.com/drugs/DB11613ApprovedInvestigationalGoals of therapy for Epclusa include the intent to cure, or achieve a sustained virologic response (SVR), after 12 weeks of daily therapy. … It is also currently the most potent HCV antiviral medication on the market with a sustained virologic response (SVR) after 12 weeks of therapy of 93-99% depending on genotype and level of cirrhosis and
Categories: Antivirals for treatment of HCV infectionsEthylenediamine
go.drugbank.com/drugs/DB14189ApprovedEthylenediamine is an organic compound that is used as a building block for the production of many other chemical products. … It is also used as an excipient in many pharmacological preparations such as creams. Notably, ethylenediamine is a contact sensitizer capable of producing local and generalized reactions [A34285].
Cemiplimab
go.drugbank.com/drugs/DB14707ApprovedInvestigationalCemiplimab is a fully human monoclonal antibody that works against programmed death receptor-1 (PD-1), which is a negative regulator of T cell function. … [L39804] Cemiplimab was first approved by the FDA on September 28, 2018, as the first FDA-approved treatment for advanced cutaneous squamous cell carcinoma (CSCC).
Isocarboxazid
go.drugbank.com/drugs/DB01247Approved[T115] It was first introduced by Roche pharmaceuticals, further developed by Validus pharms Inc and first FDA approved as a prescription drug on July 1st, 1959. … It is a monoamine oxidase inhibitor.[A31930] It is used in the treatment of major depression, dysthymic disorder, atypical disorder, panic disorder and the phobic disorders.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesElexacaftor
go.drugbank.com/drugs/DB15444ApprovedInvestigational[A187361] While dual corrector/potentiator combination therapy has proven useful in the treatment of a subset of CF patients,[A187358] their use is typically limited to patients who are homozygous for … [A187361] Elexacaftor, along with [VX-659], was designed to fill the need for an efficacious CF therapy for patients who are heterozygous for _F508del-CFTR_ and a gene that does not produce protein or
Mogamulizumab
go.drugbank.com/drugs/DB12498ApprovedInvestigational) or Sézary syndrome (SS) after at least one prior systemic therapy. … Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of